Fate Therapeutics (FATE) News Today $1.17 -0.08 (-6.40%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$1.18 +0.01 (+0.43%) As of 05/21/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock FATE Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Vestal Point Capital LP Increases Stock Position in Fate Therapeutics, Inc. (NASDAQ:FATE)Vestal Point Capital LP raised its position in shares of Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) by 46.3% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,465,000 shares of the biopharmaceutical company's stock aMay 21 at 8:14 AM | marketbeat.comFate Therapeutics, Inc. (NASDAQ:FATE) Holdings Raised by Tang Capital Management LLCTang Capital Management LLC grew its position in Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) by 165.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,855,954 shares of the biopharmaceutical company's stock after aMay 20 at 6:24 AM | marketbeat.comSphera Funds Management LTD. Purchases Shares of 397,177 Fate Therapeutics, Inc. (NASDAQ:FATE)Sphera Funds Management LTD. bought a new position in shares of Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 397,177 shares of the biopharmaceutical company's stoMay 18, 2025 | marketbeat.comFate Therapeutics (NASDAQ:FATE) Upgraded at StockNews.comMay 18, 2025 | americanbankingnews.comQ2 Earnings Estimate for Fate Therapeutics Issued By WedbushMay 18, 2025 | americanbankingnews.comRobert W. Baird Lowers Fate Therapeutics (NASDAQ:FATE) Price Target to $4.00May 17, 2025 | americanbankingnews.comFate Therapeutics' (FATE) "Hold" Rating Reiterated at Needham & Company LLCMay 17, 2025 | americanbankingnews.comWhat is Leerink Partnrs' Estimate for FATE Q2 Earnings?May 17, 2025 | americanbankingnews.comNeedham Remains a Hold on Fate Therapeutics (FATE)May 16, 2025 | theglobeandmail.comBarclays Reaffirms Their Buy Rating on Fate Therapeutics (FATE)May 16, 2025 | theglobeandmail.comFate Therapeutics (FATE) Receives a Hold from WedbushMay 16, 2025 | theglobeandmail.comFate Therapeutics (NASDAQ:FATE) Receives Hold Rating from Needham & Company LLCNeedham & Company LLC reaffirmed a "hold" rating on shares of Fate Therapeutics in a research note on Wednesday.May 16, 2025 | marketbeat.comFate Therapeutics First Quarter 2025 Earnings: Beats ExpectationsMay 15, 2025 | finance.yahoo.comFate Therapeutics, Inc. (NASDAQ:FATE) Shares Purchased by Dimensional Fund Advisors LPDimensional Fund Advisors LP grew its holdings in shares of Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) by 10.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,898,377 shares of the biopharmaceutical company's stock after purchasing anMay 15, 2025 | marketbeat.comIntegral Health Asset Management LLC Lowers Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE)Integral Health Asset Management LLC cut its position in Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) by 38.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 600,000 shares of the biopharmacMay 14, 2025 | marketbeat.comFate Therapeutics Reports First Quarter 2025 Financial Results and Business UpdatesMay 13, 2025 | globenewswire.comFate Therapeutics: Suffering The Fate Of A Depressed Cell Therapy SectorMay 9, 2025 | seekingalpha.comBaker BROS. Advisors LP Grows Position in Fate Therapeutics, Inc. (NASDAQ:FATE)Baker BROS. Advisors LP lifted its position in shares of Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) by 8.7% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 3,258,402 shares of the biopharmaceutical company's stock after buying an additional 260,May 6, 2025 | marketbeat.comFate Therapeutics, Inc. (NASDAQ:FATE) Given Average Rating of "Hold" by BrokeragesShares of Fate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) have been assigned a consensus recommendation of "Hold" from the nine ratings firms that are covering the company, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a hold recommendation and two have givMay 4, 2025 | marketbeat.comFate Therapeutics (FATE) Expected to Announce Quarterly Earnings on ThursdayFate Therapeutics (NASDAQ:FATE) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-fate-therapeutics-inc-stock/)May 3, 2025 | marketbeat.comMarshall Wace LLP Makes New Investment in Fate Therapeutics, Inc. (NASDAQ:FATE)Marshall Wace LLP bought a new position in shares of Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 512,641 shares of the biopharmaceutical company's stock, valued at approximaMay 3, 2025 | marketbeat.comFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)May 2, 2025 | globenewswire.comFate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual MeetingApril 29, 2025 | globenewswire.comRecent uptick might appease Fate Therapeutics, Inc. (NASDAQ:FATE) institutional owners after losing 66% over the past yearApril 27, 2025 | finance.yahoo.com249,800 Shares in Fate Therapeutics, Inc. (NASDAQ:FATE) Acquired by XTX Topco LtdXTX Topco Ltd bought a new stake in Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 249,800 shares of the biopharmaceutical company's stock, valued at apprApril 24, 2025 | marketbeat.comWalleye Capital LLC Has $1.79 Million Position in Fate Therapeutics, Inc. (NASDAQ:FATE)Walleye Capital LLC grew its holdings in Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) by 1,502.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,083,092 shares of the biopharmaceutical company's stock aftApril 22, 2025 | marketbeat.comCerity Partners LLC Grows Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE)Cerity Partners LLC boosted its holdings in shares of Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) by 4,953.6% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 823,134 shares of the biopharmaceutical company's stock after purchasing an additional 8April 20, 2025 | marketbeat.comFate Therapeutics receives RMAT designation from FDA for FT819April 14, 2025 | markets.businessinsider.comFate Therapeutics Stock Draws Investor Attention After FDA Grants Special Designation To Its CAR T-Cell Therapy: Retail Stays OptimisticApril 14, 2025 | msn.comFate Therapeutics gets RMAT status from FDA for Lupus treatmentApril 14, 2025 | msn.comFate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)April 14, 2025 | globenewswire.comFate Therapeutics, Inc. (NASDAQ:FATE) Receives Average Recommendation of "Hold" from AnalystsShares of Fate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) have earned an average rating of "Hold" from the nine ratings firms that are covering the firm, MarketBeat reports. Seven analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The averageApril 8, 2025 | marketbeat.comFate Therapeutics (NASDAQ:FATE) Stock Crosses Below 200 Day Moving Average - Here's What HappenedFate Therapeutics (NASDAQ:FATE) Share Price Passes Below 200-Day Moving Average - Here's What HappenedApril 5, 2025 | marketbeat.comFate Therapeutics (FATE) Down 34.6% Since Last Earnings Report: Can It Rebound?April 4, 2025 | msn.comFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)April 2, 2025 | globenewswire.comFY2025 EPS Forecast for Fate Therapeutics Boosted by AnalystFate Therapeutics, Inc. (NASDAQ:FATE - Free Report) - Analysts at Cantor Fitzgerald boosted their FY2025 EPS estimates for Fate Therapeutics in a note issued to investors on Tuesday, March 18th. Cantor Fitzgerald analyst L. Watsek now anticipates that the biopharmaceutical company will post earniMarch 21, 2025 | marketbeat.comFate Therapeutics’ SWOT analysis: promising pipeline drives stock outlookMarch 14, 2025 | investing.comFate Therapeutics (NASDAQ:FATE) Rating Lowered to "Sell" at StockNews.comStockNews.com downgraded shares of Fate Therapeutics from a "hold" rating to a "sell" rating in a report on Tuesday.March 11, 2025 | marketbeat.comBank of America Securities Keeps Their Hold Rating on Fate Therapeutics (FATE)March 10, 2025 | markets.businessinsider.comFate Therapeutics price target lowered to $2.50 from $3 at BofAMarch 10, 2025 | markets.businessinsider.comQ1 EPS Estimates for Fate Therapeutics Boosted by WedbushFate Therapeutics, Inc. (NASDAQ:FATE - Free Report) - Stock analysts at Wedbush raised their Q1 2025 EPS estimates for Fate Therapeutics in a research report issued to clients and investors on Wednesday, March 5th. Wedbush analyst D. Nierengarten now expects that the biopharmaceutical company wilMarch 10, 2025 | marketbeat.comFate Therapeutics, Inc. (NASDAQ:FATE) Just Reported, And Analysts Assigned A US$6.00 Price TargetMarch 8, 2025 | finance.yahoo.comFate Therapeutics, Inc Q4 Loss Misses EstimatesMarch 8, 2025 | nasdaq.comFate Therapeutics (NASDAQ:FATE) Price Target Lowered to $3.00 at Stifel NicolausStifel Nicolaus lowered their price objective on Fate Therapeutics from $5.00 to $3.00 and set a "hold" rating for the company in a research report on Thursday.March 7, 2025 | marketbeat.comFate Therapeutics (NASDAQ:FATE) Given New $4.00 Price Target at Wells Fargo & CompanyWells Fargo & Company lowered their target price on shares of Fate Therapeutics from $5.00 to $4.00 and set an "equal weight" rating on the stock in a report on Thursday.March 7, 2025 | marketbeat.comFate Therapeutics (NASDAQ:FATE) Earns "Neutral" Rating from WedbushWedbush reissued a "neutral" rating and issued a $5.00 price target on shares of Fate Therapeutics in a report on Thursday.March 7, 2025 | marketbeat.comNeedham & Company LLC Reiterates "Hold" Rating for Fate Therapeutics (NASDAQ:FATE)Needham & Company LLC reissued a "hold" rating on shares of Fate Therapeutics in a research note on Thursday.March 7, 2025 | marketbeat.comWedbush Remains a Hold on Fate Therapeutics (FATE)March 7, 2025 | markets.businessinsider.comFate Therapeutics (NASDAQ:FATE) Releases Earnings Results, Beats Expectations By $0.13 EPSFate Therapeutics (NASDAQ:FATE - Get Free Report) posted its earnings results on Wednesday. The biopharmaceutical company reported ($0.31) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.13. Fate Therapeutics had a negative net margin of 1,325.43% and a negative return on equity of 45.88%.March 6, 2025 | marketbeat.comFate Therapeutics (NASDAQ:FATE) Issues Quarterly Earnings ResultsFate Therapeutics (NASDAQ:FATE - Get Free Report) posted its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.31) EPS for the quarter, beating analysts' consensus estimates of ($0.44) by $0.13. Fate Therapeutics had a negative net margin of 1,325.43% and a negative return on equity of 45.88%.March 6, 2025 | marketbeat.com Get Fate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter. Email Address FATE Media Mentions By Week FATE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FATE News Sentiment▼0.640.65▲Average Medical News Sentiment FATE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FATE Articles This Week▼204▲FATE Articles Average Week Get Fate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Maravai LifeSciences News Kura Oncology News Stoke Therapeutics News Mind Medicine (MindMed) News Valneva News Opthea News Eton Pharmaceuticals News Tyra Biosciences News Relay Therapeutics News REGENXBIO News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FATE) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredWarning: Prepare to Be Shocked by These PayoutsThere's a strategy out there paying up to 70% on tech stocks like Amazon, Tesla, and Microsoft—stocks that don...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy FATE Stock Free FATE Stock Alerts